Which peptides are studied in relation to genomic instability?
A research-supply summary of the compounds appearing in the genomic-instability literature, including NMNAT-1/NAD+ biology, alpha-ketoglutarate, and the somatostatin/GHRH receptor axis, with a clear note on which finding
The peptide most directly tied to genomic instability in the supplied evidence is NMNAT-1 (nicotinamide mononucleotide adenylyltransferase 1), the major nuclear isoform of the mammalian NMNAT family. NMNAT-1 catalyzes the final step in NAD+ biosynthesis, and NAD+ is a metabolic cofactor and signaling molecule supporting redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation, and neuronal maintenance [1]. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited disease, and age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, though the causal node and limiting compartment differ across tissues and disease states [1].
The pathway context for this work is nuclear NAD+ homeostasis and its coupling to DNA-repair and chromatin machinery, rather than a single receptor family [1]. A second, distinct axis appears in the pituitary literature: somatotroph cells express cognate G protein-coupled receptors for hypothalamic stimulatory GH-releasing hormone (GHRH) and inhibitory somatostatin, and signaling through these receptors is studied as a molecular driver in nonfamilial somatotroph adenomas [2].
Research Studies
NMNAT-1 and nuclear NAD+ homeostasis in DNA repair and chromatin regulation
NMNAT-1 supplies the nuclear NAD+ pool used by enzymes involved in DNA repair and chromatin regulation, which places the enzyme upstream of processes that maintain genomic integrity [1]. The review notes that the causal node and the limiting NAD+ compartment differ between tissues and disease states, so the relationship between NMNAT-1 activity and genomic stability is not uniform across models [1].
NAD+ decline and genomic instability in the aging brain
Age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, and NAD+-dependent repair and chromatin functions are part of that framing [1]. The evidence describes an association across aging models rather than a demonstrated causal chain in humans.
NAD+ and genomic instability in the context of menopause and longevity
Menopause is described as a biological condition associated with progressive estrogen depletion and increased susceptibility to several age-associated disorders, with mitochondrial dysfunction, oxidative stress, chronic inflammation, genomic instability, and immunosenescence among the mechanisms discussed [5]. This is a review-level treatment; it does not report a peptide intervention trial.
Ovarian aging, genomic instability and the ovarian-systemic axis
Intrinsic ovarian cellular defects reported in the ovarian-aging literature include genomic instability, epigenetic shifts, and mitochondrial and proteostasis damage, which may trigger senescence-associated secretory phenotype (SASP)-related inflammaging and fibrosis [6]. A related review frames cellular senescence as a central driver of ovarian aging through cell-cycle arrest pathways and a proinflammatory senescent program [8]. Both are review-level sources.
Complement proteins and senescence-associated genomic stress
The complement system, traditionally viewed as a systemic extracellular defense mechanism, is now recognized as having essential intracellular roles, and the complosome is discussed as a modulator of cellular senescence, aging and age-related disease, with SASP-driven inflammaging as the connecting process [7]. This is a review-level source and does not report a peptide-specific genomic-instability assay.
Alpha-ketoglutarate and surgical stress in older patients
The AEGIS study examines alpha-ketoglutarate in the setting of coronary artery bypass grafting (CABG), a procedure performed in approximately 400,000 patients in the United States each year [3]. CABG invokes a surgical stress response in which systemic epinephrine increases 33-fold and norepinephrine increases 3-fold, with local tissue injury producing sterile inflammation and release of damage-associated molecular patterns (DAMPs) that activate neutrophils and drive cytokine, complement and coagulation changes [3]. The trial is registered but the supplied record does not report genomic-instability endpoints.
GHRH and somatostatin receptor signaling in somatotroph adenomas
In nonfamilial somatotroph adenomas, the work centres on G protein-coupled receptors for GHRH and somatostatin and the molecular drivers implicated in pathogenesis [2]. Excess growth hormone production leading to acromegaly most commonly emanates from an adenomatous pituitary somatotroph, and understanding this pathogenesis is framed as a route to explaining how biologic behavior affects treatment outcomes [2].
Triple-negative breast cancer and dose-dense adjuvant chemotherapy
Breast cancer is distinguished into subtypes by clinical, molecular and genetic characteristics, with treatment decisions based mainly on estrogen receptor (ER), progesterone receptor (PR) and HER2 status in correlation with the ki67 proliferation index, alongside tumor size, histological grade and lymph node status [4]. The registered study concerns survival analysis in early triple-negative breast cancer treated with dose-dense sequential adjuvant chemotherapy; the supplied record does not describe a peptide intervention [4].
Comparison of evidence contexts
| Compound or axis | Model or population in the evidence | Genomic-instability link reported |
|---|---|---|
| NMNAT-1 / NAD+ | Human genetic evidence plus aging and neurodegeneration models [1] | NAD+ supports DNA repair and chromatin regulation; decline implicated in brain aging [1] |
| NAD+ (menopause context) | Review of menopause and longevity [5] | Genomic instability listed among mechanisms [5] |
| Ovarian aging pathways | Review-level, ovarian tissue [6][8] | Genomic instability listed among intrinsic cellular defects [6] |
| Complosome | Review-level, senescence models [7] | Discussed via SASP and inflammaging [7] |
| Alpha-ketoglutarate | Registered trial in CABG patients [3] | Not reported in the supplied record [3] |
| GHRH / somatostatin receptors | Human somatotroph adenoma literature [2] | Not reported in the supplied record [2] |
If you are reading this for personal health reasons
The materials described here are sold for laboratory research use only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for any person to take any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD+ Homeostasis in Neuroprotection and Aging — https://pubmed.ncbi.nlm.nih.gov/42646333/
- [2] Pathogenesis of nonfamilial somatotroph adenomas — https://europepmc.org/article/PMC/PMC13235285
- [3] Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS) — https://clinicaltrials.gov/study/NCT07031128
- [4] Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy — https://clinicaltrials.gov/study/NCT07820228
- [5] Nicotinamide Adenine Dinucleotide and Its Anti-aging Effects in the Context of Longevity and Menopause — https://pubmed.ncbi.nlm.nih.gov/42669985/
- [6] Ovarian aging and systemic health: Mechanisms and emerging intervention strategies — https://pubmed.ncbi.nlm.nih.gov/42607669/
- [7] Complosome as a key modulator of cellular senescence, aging and age-related diseases — https://pubmed.ncbi.nlm.nih.gov/42521026/
- [8] Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives — https://pubmed.ncbi.nlm.nih.gov/42378907/